Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition

Aytu BioPharma, Inc. (NASDAQ:AYTU) is one of the best high-return penny stocks to buy now. On July 1, Lake Street Capital Markets initiated coverage on Aytu Biosciences (NASDAQ:AYTU) with a Buy rating and an $8.00 price target, citing strong prospects following its acquisition of EXXUA.

The antidepressant’s unique mechanism reportedly avoids two major side effects common in the category, giving it a competitive edge in a saturated yet underserved market. Lake Street expects EXXUA’s rollout to significantly boost Aytu’s revenue profile by FY 2027, and believes further stock gains are likely as generic concerns ease and product adoption grows.

Aytu BioPharma, Inc. (NASDAQ:AYTU) is a pharmaceutical company that develops and commercializes innovative therapies in the U.S. and globally. Its product lineup includes ADHD treatments like Adzenys XR-ODT and Cotempla XR-ODT, as well as pediatric medications such as Karbinal ER for allergies and fluoride-based multivitamins Poly-Vi-Flor and Tri-Vi-Flor for infants and children.

While we acknowledge the potential of AYTU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts.

Disclosure: None. This article is originally published at Insider Monkey.